Oct 21 (Reuters) – Fortress Biotech Inc: * FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE FIRST PATIENTS DOSED IN CRYSTALYS THERAPEUTICS’ GLOBAL PHASE 3 TRIALS OF DOTINURAD FOR THE TREATMENT OF GOUT Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
REUTERS NEXT- DIPLOMATIC ADVISER TO UAE PRESIDENT ANWAR GARGASH: (The article has been published through…
HAVANA (Reuters) -A small group of Cuban musicians, together with the top U.S. diplomat in…
MELBOURNE, Oct 22 (Reuters) - Two years after Australia's Rugby World Cup disaster in France,…
By Lisa Richwine LOS ANGELES (Reuters) -Netflix missed Wall Street's third-quarter earnings targets because of…
Oct 22 (Reuters) - First Abu Dhabi Bank PJSC: * FIRST ABU DHABI BANK Q3…
TOKYO, Oct 22 (Reuters) - Japan's Nikkei share gauge erased losses on Wednesday following a…